Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).

Sponsor
University of Pisa
Study ID
NCT03713190
Phase
PHASE2
Status
Completed

Conditions

  • End Stage Renal Disease

Eligibility Criteria

Sex
ALL
Age
30 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Empagliflozin — COMBINATION_PRODUCT
    Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.
  • Placebo — DRUG
    A substance without specific pharmacology principles

Study Details

A study of the effects of empagliflozin, a SGLT-2 inhibitor, on endogenous glucose production and plasma glucagon levels in patients with end-stage renal disease (ESRD)

Key Dates

Start date
Sep 10, 2018
Status verified
Sep 2021
Primary completion
Feb 15, 2020
Completion
Mar 15, 2020

Study Design

Enrollment
25 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Active Comparator: Empagliflozin
    SGLT-2 inhibitor
  • Placebo Comparator: placebo
    A substance without specific pharmacology principles.

Primary Outcome Measure

Changes in plasma Glucose level [ Time Frame: 2 hours ]

Related Studies